Atezolizumab in combination with bevacizumab for advanced renal cell carcinoma – first line
NIHR HSRIC
Record ID 32016001024
English
Authors' recommendations:
Atezolizumab is a new drug to treat advanced renal cell carcinoma. Renal cell carcinoma is the most common form of kidney cancer. Many people with kidney cancer show no symptoms for many years and are often diagnosed late, after the cancer has spread. Atezolizumab is delivered straight into the blood and works by altering the body's immune reaction to the cancer. Some studies have shown that atezolizumab may work best in combination with bevacizumab and may offer a new treatment option for patients with untreated advanced renal cell carcinoma.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/atezolizumab-in-combination-with-bevacizumab-for-advanced-renal-cell-carcinoma-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Angiogenesis Inhibitors
- Bevacizumab
- Carcinoma, Renal Cell
- Kidney Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.